GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
-6.77%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$287M
AUM Growth
+$287M
(-7.6%)
Cap. Flow
-$57.4M
Cap. Flow
% of AUM
-19.96%
Top 10 Holdings %
Top 10 Hldgs %
40.75%
Holding
78
New
11
Increased
22
Reduced
19
Closed
17
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$11.8M |
| 2 |
Biohaven
BHVN
|
$7.12M |
| 3 |
Rezolute
RZLT
|
$6.11M |
| 4 |
CG Oncology
CGON
|
$5.84M |
| 5 |
Corbus Pharmaceuticals
CRBP
|
$5.34M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$50.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
$11.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$9.11M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$6.65M |
| 5 |
TG Therapeutics
TGTX
|
$5.78M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biohaven
BHVN
$1.63B
| $17M | 5.33% | 490,000 +205,000 | +72% | +$7.12M |
|
2
MoonLake Immunotherapeutics
MLTX
$3.54B
| $13.2M | 4.13% | 300,000 | – | – |
|
3
Soleno Therapeutics
SLNO
$3.6B
| $12.2M | 3.83% | 300,000 +100,000 | +50% | +$4.08M |
|
4
Axsome Therapeutics
AXSM
$6.05B
| $12.1M | 3.78% | 150,000 -60,000 | -29% | -$4.83M |
|
|
5
Ascendis Pharma
ASND
$11.8B
| $11.8M | 3.7% | +86,721 | New | +$11.8M |
|
6
Vaxcyte
PCVX
$4B
| $11.3M | 3.55% | 150,000 +55,000 | +58% | +$4.15M |
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.7M | 3.37% | 240,000 +40,000 | +20% | +$1.79M |
|
8
Roivant Sciences
ROIV
$8.15B
| $10.6M | 3.31% | 1,000,000 -300,000 | -23% | -$3.17M |
|
|
9
Perspective Therapeutics
CATX
$250M
| $9.22M | 2.89% | 925,000 -5,075,000 | -85% | -$50.6M |
|
|
10
TG Therapeutics
TGTX
$4.65B
| $8.9M | 2.79% | 500,000 -325,000 | -39% | -$5.78M |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $8.69M | 2.72% | 55,000 -70,000 | -56% | -$11.1M |
|
|
12
CG Oncology
CGON
$2.04B
| $8.21M | 2.57% | 260,000 +185,000 | +247% | +$5.84M |
|
|
13
Corbus Pharmaceuticals
CRBP
$115M
| $7.92M | 2.48% | 175,000 +118,059 | +207% | +$5.34M |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $7.65M | 2.39% | 587,708 -37,292 | -6% | -$485K |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.19M | 2.25% | 350,000 +200,000 | +133% | +$4.11M |
|
16
Immunovant
IMVT
$2.56B
| $6.86M | 2.15% | 260,000 +135,000 | +108% | +$3.56M |
|
17
Tarsus Pharmaceuticals
TARS
$2.47B
| $6.39M | 2% | 235,000 -65,000 | -22% | -$1.77M |
|
18
Phathom Pharmaceuticals
PHAT
$864M
| $6.18M | 1.94% | 600,000 +115,000 | +24% | +$1.18M |
|
|
19
Rezolute
RZLT
$619M
| $6.11M | 1.91% | +1,421,501 | New | +$6.11M |
|
20
Olema Pharmaceuticals
OLMA
$375M
| $5.95M | 1.86% | 550,000 +350,000 | +175% | +$3.79M |
|
21
Spyre Therapeutics
SYRE
$996M
| $5.88M | 1.84% | 250,237 +150,237 | +150% | +$3.53M |
|
|
22
Alnylam Pharmaceuticals
ALNY
$58.5B
| $5.47M | 1.71% | 22,500 -37,500 | -63% | -$9.11M |
|
23
Apellis Pharmaceuticals
APLS
$3.48B
| $5.18M | 1.62% | 135,000 +5,000 | +4% | +$192K |
|
24
Viking Therapeutics
VKTX
$3.04B
| $5.04M | 1.58% | 95,000 +21,998 | +30% | +$1.17M |
|
25
Rhythm Pharmaceuticals
RYTM
$6.85B
| $4.82M | 1.51% | 117,388 -7,612 | -6% | -$313K |
|